Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society.
- Autori: Ghezzi,A; Grimaldi,LM; Marrosu,MG; Pozzilli, C; Comi,G; Bertolotto,A; Trojano, M; Gallo, P; Capra, R; Centonze. D; Millefiorini, E; Sotgiu, S; Brescia Morra, V; Amato,MP; Lugaresi, A; Mancardi, G; Caputo, D; Montanari, E; Provinciali, L; Durelli, L; Bergamaschi, R; Bellantonio, P; Tola, MR; Cottone, S; Savettieri, G; Tedeschi, G; MS-SIN Study Group.
- Anno di pubblicazione: 2011
- Tipologia: Articolo in rivista (Articolo in rivista)
- OA Link: http://hdl.handle.net/10447/55497
Abstract
Three years after the introduction of natalizumab(NA) therapy for the second line treatment of relapsingremitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficaciuos in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.